Render Target: STATIC
Render Timestamp: 2025-03-14T10:33:35.138Z
Commit: a619ae74f66dae0f27639e88da12bcf600e46428
XML generation date: 2025-03-07 13:06:15.763
Product last modified at: 2024-05-30T07:13:50.505Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

CYR61 Antibody #11952

We recommend the following alternatives

Filter:
  • WB

Inquiry Info. # 11952

Please see our recommended alternatives.

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 41
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CYR61 Antibody recognizes endogenous levels of total CYR61 protein.

    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro171 of human CYR61 protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    Cysteine-rich protein 61 (CYR61, CCN1) is a secreted, matrix-associated protein belonging to the CCN family, a protein group characterized primarily by its high cysteine content (1). CYR61 regulates diverse cellular events including cell proliferation, differentiation, angiogenesis, and extracellular matrix formation. Research studies have implicated CYR61 in the development or progression of various cancers, including breast, prostate, lung, and hepatocellular carcinoma (1-4). Notably, its role in promoting cancer progression appears to be context-dependent. For example, investigators have shown that overexpression of CYR61 was positively associated with invasiveness of breast cancer cell lines (2), whereas in primary prostate tumors, expression levels were inversely correlated with tumor aggressiveness (3). In additional research studies of hepatocellular carcinoma, where CYR61 expression was positively associated with cancer progression, CYR61 was shown to be transcriptionally regulated by the Wnt/β-catenin signaling pathway (1).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.